Investors


Global Licensing Agreement with Seattle Genetics

Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties; Discusses Second Quarter Fiscal 2017 Results

Date/Time : Friday, February 10, 2017, 8:00 am EST

Listen to the Webcast audio webcast


  • February 10, 2017 Global Licensing Agreement with Seattle Genetics Presentation

  • February 10, 2017 Global Licensing Agreement with Seattle Genetics Press Release

  • February 9, 2017 Second Quarter Fiscal 2017 Results and Clinical Program Developments Press Release

  • Disclaimer

    This webpage, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein.

    Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.